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BACKGROUND
Recent gains in reducing the global burden of malaria are threatened by the emergence of 
Plasmodium falciparum resistance to artemisinins. The discovery that mutations in portions 
of a P. falciparum gene encoding kelch (K13)–propeller domains are the major determinant 
of resistance has provided opportunities for monitoring such resistance on a global scale.
METHODS
We analyzed the K13-propeller sequence polymorphism in 14,037 samples collected in 
59 countries in which malaria is endemic. Most of the samples (84.5%) were obtained 
from patients who were treated at sentinel sites used for nationwide surveillance of 
antimalarial resistance. We evaluated the emergence and dissemination of mutations 
by haplotyping neighboring loci.
RESULTS
We identified 108 nonsynonymous K13 mutations, which showed marked geographic 
disparity in their frequency and distribution. In Asia, 36.5% of the K13 mutations were 
distributed within two areas — one in Cambodia, Vietnam, and Laos and the other in 
western Thailand, Myanmar, and China — with no overlap. In Africa, we observed a 
broad array of rare nonsynonymous mutations that were not associated with delayed 
parasite clearance. The gene-edited Dd2 transgenic line with the A578S mutation, which 
expresses the most frequently observed African allele, was found to be susceptible to 
artemisinin in vitro on a ring-stage survival assay.
CONCLUSIONS
No evidence of artemisinin resistance was found outside Southeast Asia and China, 
where resistance-associated K13 mutations were confined. The common African A578S 
allele was not associated with clinical or in vitro resistance to artemisinin, and many 
African mutations appear to be neutral. (Funded by Institut Pasteur Paris and others.)
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Increased efforts have substantially reduced the global burden of malaria caused by Plasmodium falciparum,1,2 but the recent gains 
are threatened by emerging resistance to arte-
misinins, the cornerstone of current first-line 
combination treatment.1,3,4 Artemisinins are ac-
tive against a large range of intraerythrocytic 
developmental stages, but their usefulness is cur-
tailed by ring-stage resistance.5,6 Clinical arte-
misinin resistance, which was first documented 
in western Cambodia,7-10 is now prevalent across 
Southeast Asia and South China.11-17 Widespread 
artemisinin resistance would have dramatic con-
sequences, since replacement therapies are lim-
ited and threatened by resistance.18-22
Therapeutic efficacy studies are the standard 
method for determining the efficacy of anti-
malarial drugs,23 but resource constraints restrict 
the numbers of sites and patients studied each 
year. The recent discovery of mutations in por-
tions of a P. falciparum gene encoding kelch 
(K13)–propeller domains as the primary deter-
minant of artemisinin resistance provided un-
precedented opportunities for improving resis-
tance monitoring.24,25 To date, 13 independent 
K13 mutations have been shown to be associated 
with clinical resistance,3,12,14,26-28 with evidence of 
independent emergence of the same mutation in 
different geographic areas.28,29 Four Asian muta-
tions (C580Y, R539T, I543T, and Y493H) have 
been validated in vitro.24-27 In regions with no 
documented clinical artemisinin resistance, scat-
tered studies have indicated that K13 mutations 
are rare.30-41 The few examples of reduced sus-
ceptibility to artemisinin-based combination ther-
apy that have been reported in Africa were unre-
lated to K13 polymorphism, apart from three 
severe pediatric cases.42-44 No data are available 
for large regions of Africa, South America, 
Oceania, Central and East Asia, Indonesia, and 
the Philippines. The risk of the emergence or 
dissemination of resistance has spurred increased 
efforts to track artemisinin resistance in all geo-
graphic areas in which malaria is endemic. The 
use of a molecular indicator of artemisinin resis-
tance is particularly timely, since rapid, large-
scale screening is needed to provide an early 
warning about emergence or invasion events.45,46
To assess the global distribution of K13 poly-
morphisms, we launched in 2014 the K13 Arte-
misinin Resistance Multicenter Assessment 
(KARMA) study, in which we analyzed parasites 
that were collected from regions in which ma-
laria is endemic, using a dedicated molecular 
toolbox and validation procedures for sequence 
data. Sequencing of the K13-propeller domain 
was combined with an analysis of flanking haplo-
types to ascertain the origin and dissemination 
of specific mutations. We performed genome 
editing to confirm the phenotypic effect of the 
most frequent African A578S mutation. This 
worldwide survey was designed to provide criti-
cal information for drug policymakers and to 
outline methods for future surveillance activities.
Me thods
Study Design, Sampling, and Oversight
Investigators from Institut Pasteur in Paris and 
in Cambodia designed the study, which was co-
ordinated by the Cambodian branch. According 
to the study design, the investigators planned to 
analyze 200 blood samples positive for P. falci-
parum that had been collected since 2012 and to 
contribute blood samples, K13 products obtained 
on polymerase-chain-reaction (PCR) assay, or K13 
sequence data (Fig. S1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). Sites that had few available sam-
ples or samples that were collected before 2012 
were included if they were located in regions in 
which K13 diversity had not been documented. 
The study was approved by a national or institu-
tional ethics committee or other appropriate au-
thority at each site, and all investigators signed 
a declaration of ethical clearance.
Samples were obtained from patients seeking 
treatment at sites involved in national surveys 
of antimalarial drug resistance, from patients 
enrolled in therapeutic efficacy studies,23 from 
asymptomatic participants who were enrolled in 
surveillance programs, and from travelers re-
turning to Europe with malaria. Investigators 
at Institut Pasteur in Cambodia collected all bio-
logic material and performed K13 sequence and 
haplotype analysis; they also conducted quality-
control analyses, and they vouch for the accuracy 
and completeness of the molecular data. Investi-
gators who conducted therapeutic efficacy studies 
vouch for the accuracy and completeness of the 
clinical data. The sponsors had no role in the 
study design or in the collection or analysis of 
the data. There was no confidentiality agreement 
between the sponsors and the investigators.
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Genotyping
The Institut Pasteur in Cambodia provided re-
agents, blinded quality-control samples, and 
standard operating procedures as a K13 toolbox 
(Table S1 in the Supplementary Appendix). DNA 
extraction and amplification of the K13-propeller 
domain (codons 440-680, 720 bp)24 were per-
formed accordingly. PCR products were sequenced 
by Macrogen. We analyzed electropherograms on 
both strands, using PF3D7_1343700 as the refer-
ence sequence. We performed external quality 
assessment that included proficiency testing (in 
which 6 blinded quality-control samples were 
tested in each 96-well sequencing plate by each 
partner) and external quality control (in which 
359 blood samples [2.6%] were independently re-
tested) (Fig. S2 in the Supplementary Appendix). 
Isolates with mixed alleles were considered to be 
mutated for the purposes of mutation-frequency 
estimation.
The PF3D7_1337500 (K13_151) and 
PF3D7_1339700 (K13_159) loci were amplified 
(Table S2 in the Supplementary Appendix) and 
DNA sequences were analyzed as indicated above. 
Individual alleles were identified for each locus 
and haplotypes generated.
A578S Gene Editing
We performed zinc-finger nuclease engineering, 
plasmid construction, and gene editing of the 
Dd2 line (which was collected in Indochina) 
with the A578S mutation.25 We assessed the in 
vitro susceptibility to artemisinin of the Dd2 
A578S mutation, the Dd2 parent, and the Dd2 
C580Y mutation (as a positive control), using the 
ring-stage survival assay (RSA) performed in red 
cells that had been infected with the malaria 
parasite in its ring stage (the developmental 
stage that is associated with resistance to arte-
misinin) for an estimated 0 to 3 hours. The cells 
were then exposed to dihydroartemisinin (the 
main metabolite of all artemisinin derivatives), 
and drug susceptibility was measured at 72 
hours.5,25
Geographical Mapping
We calculated the proportion of parasites with a 
3D7, wild-type allele (which is associated with 
artemisinin susceptibility) in each country and 
recorded the geospatial coordinates. To generate 
graphical maps, we interpolated data using ordi-
nary kriging methods (or Gaussian process re-
gression) or inverse distance weighting. (Details 
about the methods are provided in the Supple-
mentary Appendix.)
Statistical Analysis
We expressed quantitative data as medians and 
interquartile ranges or as means and 95% confi-
dence intervals. We used the Mann–Whitney test 
or t-tests of independent samples to compare 
continuous variables and the chi-square test or 
Fisher’s exact test to compare categorical vari-
ables. We obtained estimates of nucleotide diver-
sity,47 haplotype diversity,48 and Tajima’s D test49 
using DnaSP software, version 5.50 All reported P 
values are two-sided, and a P value of less than 
0.05 was considered to indicate statistical signifi-
cance. Data were analyzed with the use of Micro-
soft Excel and MedCalc software, version 12.
R esult s
Sample Collection
From May through December 2014, we gathered 
14,037 samples from 163 sites in 59 countries. 
The samples included 11,854 (84.4%) from resi-
dent malaria patients in 40 countries, 1232 (8.8%) 
from residents with asymptomatic infections in 
11 countries, and 951 (6.8%) from travelers re-
turning with falciparum malaria from 40 coun-
tries (Fig. S3 in the Supplementary Appendix). 
The samples included those obtained from 2450 
patients with malaria (2367 residents and 83 
travelers) for whom follow-up data on day 3 were 
available (Table S3 in the Supplementary Appen-
dix). We collected 4156 samples in 2012, 6440 
samples in 2013, and 1671 samples in 2014 
(>87% of all samples). Data regarding sample 
size, sex ratio, age, and parasitemia ranges ac-
cording to study site are provided in Table S4 in 
the Supplementary Appendix.
K13-Propeller Sequence Polymorphisms
Sequences were generated for 13,157 (93.7%) 
samples; 880 samples from 35 sites had sequenc-
es that could not be interpreted because of poor 
quality or an insufficient quantity of DNA. 
Nearly all the samples (99.2%) contained a sin-
gle K13 allele; 108 of 111 polyclonal infections 
were identified in samples obtained in Africa. 
The minor allele in a mixed sample was detected 
when its proportion was more than 20% (Fig. S4 
in the Supplementary Appendix).
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Overall, 1250 samples (9.5%) had 1295 K13 
mutations, including 1097 (84.7%) with nonsyn-
onymous mutations and 198 (15.3%) with synony-
mous mutations; 186 alleles were identified 
(Table S5 and Fig. S5 in the Supplementary Ap-
pendix). Among these alleles, there were 108 
nonsynonymous mutations, of which 70 were 
newly identified and 38 were among 103 that 
had been reported previously.12,14,17,24,28,31-35,37-40,51-57
Only 9 nonsynonymous mutations (C580Y, F446I, 
R539T, A578S, Y493H, P574L, P553L, N458Y, and 
R561H) had a frequency of more than 1%; 72 
alleles were observed only once (Tables S6 and 
S7 in the Supplementary Appendix).
There was marked geographic disparity in the 
proportion and distribution of K13 polymor-
phisms. We measured nucleotide diversity, haplo-
type diversity, and Tajima’s D ratio to highlight 
the continent-specific frequency of mutant alleles 
(Fig. S6 in the Supplementary Appendix). Of the 
1097 nonsynonymous mutations, 957 (87.2%) 
were observed in samples obtained in Asia, and 
169 of the 198 synonymous mutations (85.4%) 
were observed in samples obtained in Africa.
 Continental Distribution and Proportion 
of K13-Propeller Mutations
The proportion of K13 nonsynonymous muta-
tions was heterogeneous in Asia, ranging from 
fixed (>95%) to very high (80 to 94%) in western 
Cambodia (Fig. S7 in the Supplementary Appen-
dix), to intermediate (40 to 50%) in Myanmar and 
Vietnam, to moderate (10 to 20%) in eastern Cam-
bodia, Thailand, China, and Laos, to low (<5%) 
elsewhere (Fig. 1). In South America, Oceania, 
and Africa, K13 nonsynonymous mutations were 
uncommon, except for a few African countries 
(range, 3.0 to 8.3% in Gambia, Central African 
Republic, Zambia, Comoros, Guinea, Kenya, 
and Chad). K13 nonsynonymous mutations were 
not detected in 27 countries from which sam-
ples were obtained (19 in Africa, 2 in Asia, 1 in 
Oceania, and 5 in South America), as shown on 
maps of wild-type allele distribution (Fig. 2).
Individual K13 nonsynonymous mutations 
showed restricted geographic localization. In 
Asia, two distinct areas were identified, with 
different frequencies of individual mutations: 
one area that includes Cambodia, Vietnam, and 
Laos, where C580Y, R539T, Y493H, and I543T 
mutations were frequent or specific, and a second 
area that includes western Thailand, Myanmar, 
and China, where F446I, N458Y, P574L, and R561H 
mutations were specific (Fig. S8 in the Supple-
mentary Appendix). The P553L allele was distrib-
uted in the two areas (Fig. 3).
Figure 1. K13 Nonsynonymous Mutations, According to Country and Continent.
Shown are the percentages of nonsynonymous mutations that have been 
identified in the portion of the Plasmodium falciparum K13 gene encoding 
the kelch­propeller domain in Asia, Africa, South America, and Oceania. 
Synonymous mutations that do not modify the protein sequence are not 
indicated. At present, all the mutations that have been associated with re­
sistance to artemisinin derivatives have resulted in nonsynonymous amino 
acid changes. The black circles indicate medians and the I bars interquar­
tile ranges for each continent. K13 nonsynonymous mutations were not de­
tected in 27 countries from which samples were obtained (19 in Africa, 2 in 
Asia, 1 in Oceania, and 5 in South America). Names are not shown (owing 
to a lack of space) for the following countries: in Asia: Afghanistan, Iran, 
Bangladesh, Nepal, Indonesia, and Philippines; in Africa: Cameroon, Congo, 
Democratic Republic of Congo, Equatorial Guinea, Gabon, Burundi, Ethio­
pia, Rwanda, Sudan, South Sudan, Somalia, Tanzania, Uganda, Madagascar, 
Angola, Malawi, Mozambique, South Africa, Zimbabwe, Benin, Burkina Faso, 
Ghana, Guinea Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, 
Senegal, Sierra Leone, and Togo; in South America: Brazil, Colombia, Ecua­
dor, French Guiana, Peru, and Venezuela; and in Oceania: Papua New Guin­
ea and Solomon Islands. The percentages for Chad and Gambia were de­
rived from a sample size of less than 50. Details regarding sampling and 
K13 diversity according to country are provided in Tables S4, S5, and S7 
and Fig. S3 in the Supplementary Appendix. CAR denotes Central African 
Republic.
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Figure 2. Frequency Distribution of the Wild-Type K13 Allele.
Shown are the distributions of the wild­type K13 allele in Asia (Panel A) and around the world (Panel B). Areas in which malaria is endemic 
are shaded in gray, and areas that are considered to be malaria­free are shown in white. The mean frequency of the wild­type allele is indi­
cated by the color code. In Panel A, the individual sites of sample collection are indicated with a cross. In Panel B, a 100­km radius was 
used for the area centered on each sampling site or on the capital city of the country if no specific site was used for sampling. Data re­
garding sampling methods and K13 diversity according to country are provided in Tables S4, S5, and S7 and Fig. S3 in the Supplementary 
Appendix.
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In Africa, no Asian artemisinin-resistance al-
lele was observed among 9542 sequences, but 150 
distinct alleles were identified, 92% of which 
were found in only one or two samples. Apart 
from A578S, V589I, S522C, V534A, F583L, and 
G665C, most alleles were Africa-specific and local-
ized. A578S, which ranked fourth in abundance 
among mutant isolates, was observed in 1 sam-
ple from Thailand and 41 samples from Africa 
(Tables S6 and S7 in the Supplementary Appendix).
 New Emergence or Dissemination?
We investigated the genetic relatedness of iso-
lates harboring the same frequent K13 mutation 
by assessing the polymorphism of two neighbor-
ing loci. We observed 10 alleles for K13_151 and 
42 alleles for K13_159, which resulted in 80 
flanking haplotypes (Tables S8 and S9 in the 
Supplementary Appendix). This assessment iden-
tified numerous emergence events alongside 
spreading of a small group of mutations for 
Figure 3. Overview of the Distribution of the Flanking Haplotypes of the C580Y, Y493H, R539T, I543T, P553L, P574L, 
and F446I Nonsynonymous Mutations in K13 in Two Regions in Asia.
Shown are two areas in Asia in which individual K13 nonsynonymous mutations (which are labeled in the colored 
boxes) were frequently identified: one area that includes Cambodia, Vietnam, and Laos and a second area that in­
cludes western Thailand, Myanmar, and China. The haplotype groups of C580Y, F446I, P574L, and P553L are shown 
in distinct colors. Similarly colored boxes indicate shared haplotypes, and hatched boxes indicate the presence of 
additional country­specific haplotypes. For example, C580Y haplotypes that are shared between Cambodia, Vietnam, 
and Laos (H29, H33, or H43) are shown in red, whereas the C580Y haplotype found in Thailand (H42) is shown in 
light blue. Full details about the distribution of haplotypes are provided in Table S9 and Fig. S9 in the Supplementary 
Appendix.
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artemisinin resistance (Fig. 3). Of 17 distinct 
C580Y haplotypes, 3 common haplotypes were 
distributed across Cambodia, Vietnam, and Laos 
and 14 in specific areas of Cambodia, Thailand, 
and Vietnam. Similar observations were made 
for the Y493H, R539T, and I543T haplotypes, 
with probable west-to-east dissemination for the 
Y493H and R539T mutations and movement from 
Vietnam to eastern Cambodia for I543T muta-
tions. Three prevalent F446I haplotypes were 
distributed across Myanmar, and 8 haplotypes 
were localized within China or Myanmar. Site-
specific localization was observed for the 5 P553L 
haplotypes, the 6 P574L haplotypes, and the 
2 E605K and R561H haplotypes (Fig. S9 in the 
Supplementary Appendix). For the common 
African mutation A578S, we identified multiple 
independent events of emergence (31 different 
haplotypes among 35 isolates) (Fig. S10 in the 
Supplementary Appendix).
Testing of the A578S Allele for Artemisinin 
Resistance
We wanted to evaluate whether the A578S muta-
tion had a selective advantage against artemis-
inin, since there have been reports about a con-
flicting phenotype of the allele,12,31,36,44 which 
has been found at multiple sites in Africa and 
Asia12,31,32,34-40,57 (Table S6 and Fig. S10 in the 
Supplementary Appendix). We therefore intro-
duced the A578S mutation in the Dd2 line that 
had been used to investigate the effect of several 
Asian K13 mutations.25 The Dd2 line with the 
A578S mutation was susceptible to artemisinin on 
RSA. The survival rate (mean [±SE], 0.29±0.11%) 
was equivalent to that in the parental line (mean, 
0.14±0.03%), which was unlike the survival rate 
(mean, 4.01±0.16%) in the positive control Dd2 
line with the C580Y mutation (Fig. S11 in the 
Supplementary Appendix).
K13 Mutations and Positivity Rate
Our sampling included 2450 patients in whom 
the presence of parasites was assessed on day 3 
after 7 days of artesunate monotherapy or a stan-
dard 3-day course of artemisinin-based combi-
nation therapy. Of these patients, 121 had posi-
tive parasite results on day 3 (Table S3 in the 
Supplementary Appendix). Of 40 nonsynonymous 
mutations that were detected in isolates obtained 
from these patients, only 8 were associated with 
positivity on day 3 (F446I, N458Y, N537D, R539T, 
I543T, P553L, P574L, and C580Y); all these al-
leles were observed only in Southeast Asia and 
China (Fig. S12 in the Supplementary Appendix). 
No circulating blood-stage parasites were found 
on day 3 in samples obtained from 1533 African 
patients in 25 countries, except for 9 patients 
who were each carrying a wild-type allele. The 
9 African patients who were carrying an A578S 
allele on day 0 were parasite-free on day 3.
Discussion
In this study, we have attempted to profile the 
global distribution of K13 polymorphisms. The 
breadth of this survey, with 163 sites that were 
sampled for molecular mapping and 36 coun-
tries with data regarding therapeutic efficacy, 
led us to conclude that artemisinin resistance is 
confined to Southeast Asia and China, where 
resistance-associated K13 mutations have reached 
intermediate frequency to fixation. This status 
contrasts with the situation in South America, 
Oceania, the Philippines, and Central and South 
Asia, which are essentially free of nonsynony-
mous K13 mutations. We observed many highly 
diverse, low-frequency nonsynonymous mutations 
in Africa, although none of these mutations were 
associated with clinical artemisinin resistance, as 
assessed by the presence of parasites on day 3 
after artesunate monotherapy or 3-day treatment 
with artemisinin-based combination therapy. We 
saw no evidence of invasion of Africa by Asian 
resistance-conferring alleles, a finding that was 
consistent with the results of previous smaller 
studies.35-38,40,41,44,58,59 Finally, no positive selection 
was observed aside from that in Asia, which sug-
gests no immediate threat to artemisinin efficacy 
in most countries in which malaria is endemic.
In the two independent foci of resistance that 
have been identified in the region that includes 
Cambodia, Vietnam, and Laos and the one that 
includes western Thailand, Myanmar, and China, 
we observed many more examples of emergence 
of resistance-associated mutations than had been 
reported previously.28,29,55 This finding indicates 
that contemporary artemisinin resistance is a 
result of numerous independent emergence events 
involving the same mutations together with the 
dissemination of a small group of endemic mu-
tations (Fig. 3). The endemic mutations are 
probably the oldest ones, as suggested by an 
analysis of our archived samples, which showed 
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that all four common contemporary C580Y haplo-
types that were observed in Cambodia were 
already quite frequent 10 years earlier in Pailin 
province, the epicenter of the emergence of arte-
misinin-resistant parasites (Table S9 in the Sup-
plementary Appendix).9,10 We observed no over-
lap between the sets of mutations and haplotypes 
in the two main resistance areas in Asia, which 
suggests the presence of different selective pres-
sures in the two areas. Such differences may 
stem from the use of different artemisinin-based 
combination therapies as first-line treatment, dif-
ferent types of founder populations,29,59 or differ-
ent epidemiologic ecosystems.
To date, 13 nonsynonymous mutations have 
been associated with slow parasite clear-
ance,3,12,24,25,28,32 and 4 mutations have been vali-
dated as conferring an increased rate of ring-
stage survival in drug-resistant field isolates in 
vitro24 or in gene-edited parasite lines.45 In the 
KARMA study, 8 nonsynonymous mutations 
that were observed in Southeast Asia and China 
— F446I, N458Y, N537D, R539T, I543T, P553L, 
P574L, and C580Y — were associated with posi-
tive results on day 3, findings that were consis-
tent with data from previous studies that used 
parasite-clearance half-lives to identify artemis-
inin resistance12,14,24,26-28 and that provide further 
evidence of the positivity rate on day 3 as a 
sensitive indicator of clinical resistance to arte-
misinins.
The A578S mutation that has been commonly 
observed in Africa12,35-40,44 and detected in India,31 
Bangladesh,34 and Thailand was sensitive on in 
vitro RSAs; this finding was unrelated to positiv-
ity on day 3. Numerous events of independent 
emergence were observed with no evidence of 
dissemination. These findings are consistent with 
the sensitive phenotype of one A578S Ugandan 
parasite as seen on RSA performed ex vivo (i.e., 
in samples obtained directly from patients)36 or 
the lack of association with slow-clearing infec-
tions in earlier studies.12,31 Thus, except for one 
recent study involving a few severely ill chil-
dren,44 the available data suggest that A578S is 
not an artemisinin-resistance mutation.
Aside from nine patients who carried wild-
type K13 alleles, there was no positivity on day 3 
among African patients. This result is consistent 
with the finding that a large number of rare K13 
alleles are neutral with respect to artemisinin 
susceptibility and with the lack of evidence of 
artemisinin-driven selection on the K13 locus in 
Africa (Table S5 in the Supplementary Appen-
dix). However, clinical detection of artemisinin 
resistance in Africa is complicated by the contri-
bution of acquired immunity and maintained 
efficacy of the partner drugs (amodiaquine and 
lumefantrine) to parasite clearance.60,61 In vitro 
phenotyping with the use of RSA5 and allele-
specific genome-editing studies25 can provide im-
portant information about the potential pheno-
typic effect of nonsynonymous mutations with 
respect to artemisinin susceptibility, as we pro-
vided for A578S in this study. Similar approach-
es could be used to assess the potential effect of 
frequently observed K13 nonsynonymous muta-
tions associated with clinical artemisinin resis-
tance (e.g., F446I, N458Y, P574L, and P553L). Of 
108 nonsynonymous mutations that were detect-
ed, we observed 72 only once, which was consis-
tent with the results of earlier studies.35,37-41 The 
criteria for prioritizing further laboratory studies 
include the following: the frequent observation 
of a new allele with a nonsynonymous mutation, 
evidence of dissemination (since the absence of 
dissemination probably indicates that the muta-
tion was lost to genetic drift or intrapopulation 
competition), and preliminary association with 
clinical data whenever possible.
Some clues about the phenotypic effect of 
newly discovered mutations might also be ob-
tained from exploring specific metabolic changes 
(e.g., in phosphatidylinositol 3-phosphate levels62) 
in parasites with K13 mutations or modeling the 
consequences of the mutations on K13 protein 
structure. The recently solved BTB–POZ (broad 
complex–tramtrack–bric-a-brac–poxvirus and zinc-
finger) propeller structure of K13 protein do-
mains (UniProtKB accession number, PDB AYY8) 
showed that F446, Y493, R539, and C580 are 
located in a beta sheet of their respective kelch 
domains (Fig. S13 in the Supplementary Appen-
dix); these mutations should alter the overall 
structure (Fig. S14 in the Supplementary Appen-
dix). We predict that A578S, located in the flex-
ible junction between blade 3 and blade 4 of the 
beta sheet, has a limited effect on the propeller 
structure.
Our study has several weaknesses. First, the 
isolates that we evaluated represent only a con-
venience sample of those in the total population 
areas that we surveyed. Second, we lacked infor-
mation about regions in which malaria is en-
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demic such as India, where we needed to clarify 
the western boundary of resistance distribution. 
Third, in some countries, the numbers of avail-
able samples were small. The numbers of sites 
surveyed in East Africa, the Philippines, Indone-
sia, and South America need to be increased in 
future studies, although we could still discern 
clear geographic patterns in the distribution of 
haplotypes. Investigators should be able to im-
plement the K13 toolbox in the field. We expect 
that future surveillance will fill in the gaps of 
the existing map.
Figure 4. Algorithm for Surveillance of Artemisinin Resistance on the Basis of K13 Mutations.
Shown is a step­by­step procedure for acquiring information to help develop policies regarding the use of artemisinin­based combination 
therapy (ACT) and strategies to eliminate malaria. K13 genotyping is integrated into surveillance activities by combining clinical efficacy 
studies with in vitro susceptibility testing and is supported by gene­editing studies. The validated or confirmed K13 mutations that are 
associated with resistance to artemisinins are Y493H, R539T, I543T, and C580Y, and the associated K13 mutations are P441L, F446I, 
G449A, N458Y, P553L, R561H, V568G, P574L, and A675V.3 The validation of a K13 mutation as a resistance marker (i.e., confirmed K13 
mutation) is based on the following criteria: a significant association with delayed clearance of Plasmodium falciparum and a reduced 
drug sensitivity (survival rate, >1%) on ex vivo ring­stage survival assay (RSA) or in vitro RSA performed on field isolates, culture­adapted 
parasites, or gene­edited parasite lines, as compared with the K13 wild­type parent control. A K13 mutation is deemed to be associated 
with artemisinin resistance if it has a significant association with delayed clearance. A K13 mutation is said to be neutral if it has no sig­
nificant association with delayed clearance or reduced drug sensitivity. A new K13 mutation is one that has been never observed and 
thus does not appear in mutation databases. Recommendations regarding efficacy trials and treatment policies are provided by the 
World Health Organization (WHO).4
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In conclusion, our study clarifies how K13 
monitoring can assist future surveillance of ar-
temisinin resistance (Fig. 4). In regions where 
resistance is established, K13 sequencing can 
map its geographic distribution and invasion of 
the fringes. The dissemination of K13 mutations 
can be conveniently assessed by determining the 
identity of flanking haplotypes, as we did here, 
which provides a more accessible approach than 
whole-genome sequencing29 or microsatellite typ-
ing.55 In resistance-free areas, molecular surveil-
lance will need to detect possible invasion by 
known alleles associated with K13 resistance and 
track any temporal increase in the proportion 
and dissemination of newly identified nonsyn-
onymous mutations. This strategy should identify 
foci to be targeted for further in vitro phenotyp-
ing and therapeutic efficacy studies as well as 
for surveillance of other candidate artemisinin-
susceptibility loci.42,43 This effort can contribute 
information to characterize these areas with re-
spect to potential artemisinin resistance and 
inform treatment guidelines before large-scale 
dissemination has occurred.
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